###begin article-title 0
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
###end article-title 0
###begin p 1
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 245 248 <span type="species:ncbi:29255?0.12">GLV</span>
Conceived and designed the experiments: RR. Performed the experiments: LPR IC PM. Analyzed the data: JJS. Wrote the paper: RR JJS MT. Included patients in the trial. Included patients in the trial: MC TM MP MD MAS UJ PD IB JAM RdlP SC DI JMS RI GLV JO NR. Supervised the laboratory work: MT.
###end p 1
###begin p 2
Current address: Hospital 12 de Octubre, Madrid, Spain
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
Median survival is 10 months and 2-year survival is 20% in metastatic non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy. A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib. Experimental evidence suggests that BRCA1 overexpression enhances sensitivity to docetaxel and resistance to cisplatin. RAP80 and Abraxas are interacting proteins that form complexes with BRCA1 and could modulate the effect of BRCA1. In order to further examine the effect of EGFR mutations and BRCA1 mRNA levels on outcome in advanced NSCLC, we performed a prospective non-randomized phase II clinical trial, testing the hypothesis that customized therapy would confer improved outcome over non-customized therapy. In an exploratory analysis, we also examined the effect of RAP80 and Abraxas mRNA levels.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">Patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 706 714 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 1018 1026 <span type="species:ncbi:9606">patients</span>
We treated 123 metastatic non-squamous cell lung carcinoma patients using a customized approach. RNA and DNA were isolated from microdissected specimens from paraffin-embedded tumor tissue. Patients with EGFR mutations received erlotinib, and those without EGFR mutations received chemotherapy with or without cisplatin based on their BRCA1 mRNA levels: low, cisplatin plus gemcitabine; intermediate, cisplatin plus docetaxel; high, docetaxel alone. An exploratory analysis examined RAP80 and Abraxas expression. Median survival exceeded 28 months for 12 patients with EGFR mutations, and was 11 months for 38 patients with low BRCA1, 9 months for 40 patients with intermediate BRCA1, and 11 months for 33 patients with high BRCA1. Two-year survival was 73.3%, 41.2%, 15.6% and 0%, respectively. Median survival was influenced by RAP80 expression in the three BRCA1 groups. For example, for patients with both low BRCA1 and low RAP80, median survival exceeded 26 months. RAP80 was a significant factor for survival in patients treated according to BRCA1 levels (hazard ratio, 1.3 [95% CI, 1-1.7]; P = 0.05).
###end p 6
###begin title 7
Conclusions/Significance
###end title 7
###begin p 8
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Chemotherapy customized according to BRCA1 expression levels is associated with excellent median and 2-year survival for some subsets of NSCLC patients , and RAP80 could play a crucial modulating effect on this model of customized chemotherapy.
###end p 8
###begin title 9
Trial Registration
###end title 9
###begin p 10
ClinicalTrials.gov 
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Fossella1">[1]</xref>
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Scagliotti1">[2]</xref>
###xml 289 292 289 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Cobo1">[3]</xref>
###xml 339 342 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Fossella1">[1]</xref>
###xml 344 347 344 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Scagliotti1">[2]</xref>
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Cobo1">[3]</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
The median survival of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) is only 10-11 months with either standard cisplatin-based chemotherapy [1], [2] or customized cisplatin-based chemotherapy based on excision repair cross-complementing 1 (ERCC1) mRNA expression,[3] and the two-year survival rate is only 14-21%.[1], [2], [3]
###end p 12
###begin p 13
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Guha1">[4]</xref>
###xml 351 354 351 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Lynch1">[5]</xref>
###xml 356 359 356 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Paez1">[6]</xref>
###xml 361 364 361 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Pao1">[7]</xref>
###xml 434 437 434 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Sequist1">[8]</xref>
###xml 547 550 547 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Taron1">[9]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Costa1">[10]</xref>
###xml 764 768 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Marchetti1">[11]</xref>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
The two proto-oncogenes currently known to be more commonly mutated in lung adenocarcinoma are K-RAS and EGFR[4]. Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) - mainly either deletion at exon 19 or L858R mutation at exon 21 - respond to small molecule tyrosine kinase inhibitors (gefitinib and erlotinib),[5], [6], [7] with a recently reported median survival to gefitinib of 17.5 months.[8] Response rate was 90% in our retrospective trial examining EGFR mutations in patients treated with gefitinib,[9] and pooled data of prospective trials of gefitinib in patients with EGFR mutations showed a response rate of 80%.[10] However, no EGFR mutations were found in 454 patients with squamous cell carcinoma of the lung.[11]
###end p 13
###begin p 14
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Lafarge1">[12]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Husain1">[13]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Bhattacharyya1">[14]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Abbott1">[15]</xref>
###xml 473 477 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Mullan1">[16]</xref>
###xml 587 591 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn1">[17]</xref>
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Chabalier1">[18]</xref>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn2">[19]</xref>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn1">[17]</xref>
###xml 1006 1010 1006 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang1">[20]</xref>
###xml 1048 1052 1048 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Taron2">[21]</xref>
###xml 1071 1075 1071 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn2">[19]</xref>
###xml 1222 1226 1222 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn2">[19]</xref>
###xml 1228 1232 1228 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Taron2">[21]</xref>
###xml 1335 1339 1335 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn2">[19]</xref>
###xml 881 889 <span type="species:ncbi:9606">patients</span>
###xml 1076 1084 <span type="species:ncbi:9606">patients</span>
###xml 1251 1259 <span type="species:ncbi:9606">patients</span>
A growing body of evidence indicates that the breast cancer susceptibility gene 1 (BRCA1) confers sensitivity to apoptosis induced by antimicrotubule drugs (paclitaxel and vincristine) but induces resistance to DNA-damaging agents (cisplatin and etoposide) and radiotherapy.[12], [13], [14], [15] These pre-clinical findings are supported by a variety of experimental models in breast and ovarian cancer cells: inducible expression of BRCA1 enhanced paclitaxel sensitivity;[16] a short interfering RNA-mediated inactivation of endogenous BRCA1 led to paclitaxel and docetaxel resistance;[17], [18], [19] and reconstitution of BRCA1-deficient cells with wild-type BRCA1 enhanced sensitivity to paclitaxel and vinorelbine.[17] This differential modulating effect of BRCA1 mRNA expression was also observed in tumor cells isolated from malignant effusions of NSCLC and gastric cancer patients, where BRCA1 mRNA levels correlated negatively with cisplatin sensitivity and positively with docetaxel sensitivity.[20] Two retrospective studies - in NSCLC [21] and ovarian cancer[19] patients - found that low or intermediate BRCA1 mRNA levels correlated with a significantly longer survival following platinum-based chemotherapy,[19], [21] while survival in patients with higher BRCA1 expression increased following taxane-based chemotherapy.[19]
###end p 14
###begin p 15
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Harper1">[22]</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang2">[23]</xref>
###xml 449 453 449 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Sobhian1">[24]</xref>
###xml 455 459 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Kim1">[25]</xref>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang2">[23]</xref>
BRCA1 is recruited to the sites of DNA breaks, playing a central role in DNA repair and in cell-cycle checkpoint control. Binding of the mediator of DNA damage checkpoint 1 (MDC1) protein to the phosphorylated tail of histone H2AX facilitates the formation of BRCA1 nuclear foci at double-strand breaks.[22] The receptor-associated protein 80 (RAP80) acts upstream of BRCA1 and is required for the accumulation of BRCA1 to sites of DNA breaks.[23], [24], [25] Abraxas recruits RAP80 to form a complex with BRCA1. Both Abraxas and RAP80 are required for DNA damage repair, and cells depleted of Abraxas or RAP80 exhibit hypersensitivity to irradiation.[23]
###end p 15
###begin p 16
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">Patients</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
In order to examine whether customizing treatment could improve outcome in advanced NSCLC patients, we have performed a prospective non-randomized phase II trial of customized treatment based on EGFR mutation status and BRCA1 mRNA expression levels. We opted to limit enrollment to non-squamous cell carcinoma in order to maximize the opportunity to administer erlotinib in patients with EGFR mutations. Patients with either the exon 19 deletion or the L858R mutation received erlotinib, while those with wild-type EGFR received chemotherapy based on BRCA1 levels: those with low levels received cisplatin plus gemcitabine; those with intermediate levels received cisplatin plus docetaxel; and those with high levels received docetaxel alone. In an exploratory analysis, we also examined the effect of RAP80 and Abraxas mRNA levels in these patients.
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 18
###begin p 19
###xml 102 110 102 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005133-g001">Figure 1</xref>
###xml 1330 1338 1330 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005133-g001">Figure 1</xref>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
Between March 2005 and July 2007, a total of 123 patients from 25 centers were enrolled in the study (Figure 1). Thirty-five patients were excluded: 3 patients had no tumor cells in the biopsy; 5 patients had less than 50 tumor cells in the biopsy, making it impossible to assure correct results; 19 patients were wild-type EGFR but with insufficient tumor sample after EGFR assessment for BRCA1 expression analysis; 2 patients refused to participate; and 6 patients were withdrawn by their physician due to clinical factors unrelated to the study. For all 123 patients, RNA isolation and PCR amplification were successful. On average, results of genetic analyses were available in 8 days (range, 6-11 days). The median number of cycles of chemotherapy administered in the BRCA1 groups was 5 (range, 1.8). Median follow-up was 8 months (range, 1-28 months). Twelve patients had EGFR mutations and were assigned to receive erlotinib (EGFR group). Of the 111 patients with wild-type EGFR, 38 were in the lowest tercile of BRCA1 expression and were assigned to receive cisplatin plus gemcitabine (low BRCA1 group), 40 were in the intermediate tercile and were assigned to receive cisplatin plus docetaxel (intermediate BRCA1 group), and 33 were in the highest tercile and were assigned to receive docetaxel alone (high BRCA1 group) (Figure 1).
###end p 19
###begin title 20
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Consolidated Standards of Reporting Trials diagram showing flow of patients through study.
###end title 20
###begin p 21
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
Between March 2005 and July 2007, a total of 123 patients from 25 centers were enrolled in the study. Reasons for patient withdrawal: 3 patients had no tumor cells in the biopsy; 5 patients had less than 50 tumor cells in the biopsy, making it impossible to assure correct results; 19 patients were wild-type EGFR but with insufficient tumor sample after EGFR assessment for BRCA1 expression analysis; 2 patients refused to participate; and 6 patients were withdrawn by their physician due to clinical factors unrelated to the study. The two patients in the EGFR group who were not evaluable for response died within a month of entering the study; the 13 patients in the BRCA1 who were not evaluable for response received >3 cycles of treatment.
###end p 21
###begin p 22
###xml 61 68 61 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t001">Table 1</xref>
###xml 73 81 73 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s002">Table S1</xref>
###xml 576 584 576 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s003">Table S2</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">Patients</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
The clinical characteristics of the four groups are shown in Table 1 and Table S1. Median age for all patients was 60 years. Proportionally more females than males were in the lowest tercile of BRCA1 expression. EGFR mutations were more frequently observed in never-smokers (P = 0.03) and females (P = 0.0001). Fifty-five percent of patients had a performance status of 1, and 83% had stage IV disease. Seventeen percent of patients had brain metastases. Patients with EGFR mutations had a median of two metastatic sites, compared to one site in patients with wild-type EGFR (Table S2).
###end p 22
###begin title 23
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 23
###begin p 24
ECOG, Eastern Cooperative Oncology Group; PS, performance status; NR, not recorded; adeno, adenocarcinoma; BAC, bronchioloalveolar carcinoma; LCC, large cell carcinoma; NOS, non-specified;
###end p 24
###begin p 25
###xml 159 166 159 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t002">Table 2</xref>
###xml 353 360 353 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t002">Table 2</xref>
The overall response rate was 90% for the EGFR group, 25% for the low BRCA1 group, 45.7% for the intermediate BRCA1 group, and 41.9% for the high BRCA1 group (Table 2). In the intent-to-treat analysis, the response rate was 75% for the EGFR group, 21.1% for the low BRCA1 group, 40% for the intermediate BRCA1 group, and 39.4% for the high BRCA1 group (Table 2).
###end p 25
###begin title 26
Outcomes according to treatment groups
###end title 26
###begin p 27
ORR, overall response rate; TTP, time to progression; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ND, not determined; MS, median survival
###end p 27
###begin p 28
###xml 636 643 636 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t002">Table 2</xref>
###xml 645 653 645 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005133-g002">Figure 2</xref>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
Median survival was not reached but exceeded 28 months for the EGFR group, compared to 10 months (95% CI, 8.5 to 15-5) for patients in all three BRCA1 groups. Two-year survival for patients in the EGFR group was 73.3% and for all patients in the BRCA1 groups it was 26.7%. For patients in the low BRCA1 group, median survival was 11 months (95% CI, 1.1 to 20.9) and 2-year survival was 41.2%. For those in the intermediate BRCA1 group, median survival was 9 months (95% CI, 5.4 to 12.6) and 2-year survival was 15.6%. For patients in the high BRCA1 group, median survival was 11 months (95% CI, 8.2 to 13.8) and 2-year survival was 0% (Table 2, Figure 2).
###end p 28
###begin title 29
Median survival according to treatment group.
###end title 29
###begin p 30
###xml 245 252 245 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t002">Table 2</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
Median survival was not reached for 12 patients in the EGFR group, 11 months for 38 patients in the low BRCA1 group, 9 months for 40 patients in the intermediate BRCA1 group, and 11 months for 33 patients in the high BRCA1 group (P = 0.01) (see Table 2).
###end p 30
###begin p 31
###xml 368 375 368 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t002">Table 2</xref>
###xml 377 386 377 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s010">Figure S1</xref>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
Median time to progression was 13 months (95% CI, 7.7 to 18.3) in the EGFR group, compared to 6 months (95% CI, 4.7 to 7.2) for patients in all three BRCA1 groups. For patients in the low and intermediate BRCA1 groups, time to progression was 5 months (95% CI, 2.7 to 7.3). For patients in the high BRCA1 group, time to progression was 8 months (95% CI, 5.1 to 10.9) (Table 2, Figure S1).
###end p 31
###begin title 32
RAP80 and Abraxas mRNA transcripts
###end title 32
###begin p 33
###xml 43 47 43 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang2">[23]</xref>
###xml 49 53 49 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Sobhian1">[24]</xref>
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Kim1">[25]</xref>
###xml 523 531 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s004">Table S3</xref>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 258 265 <span type="species:ncbi:9606">Patient</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
Based on the results of experimental models[23], [24], [25], an exploratory analysis of the relation between BRCA1, RAP 80 and Abraxas mRNA expression was performed in 86 of 111 patients without EGFR mutations for whom sufficient tumor tissue was available. Patient characteristics for these 86 patients were similar to those of all 111 patients; significantly more females than males had low BRCA1 expression (P = 0.009). Response was significantly higher in patients with intermediate and high BRCA1 levels (P = 0.004). (Table S3). A close correlation was found between BRCA1 and RAP 80 levels (rho = 0.27; P = 0.02) and between RAP 80 and Abraxas levels (rho = 0.41; P<0.001) but not between BRCA1 and Abraxas levels (rho = 0.10; P = 0.39).
###end p 33
###begin p 34
###xml 253 260 253 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t003">Table 3</xref>
###xml 262 270 262 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005133-g003">Figure 3</xref>
###xml 703 710 703 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t003">Table 3</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
Median survival was influenced by RAP 80 levels. In patients with low BRCA1 levels, median survival was not reached in patients with low RAP 80 levels, while it was 8 months for patients with intermediate RAP 80 and 7 months for those with high RAP 80 (Table 3, Figure 3). In patients with intermediate BRCA1 levels, median survival was 5 months in patients with low RAP 80 levels, while it was 13 months for patients with intermediate RAP 80 levels and 16 months for those with high RAP 80 levels. In patients with high BRCA1 levels, median survival was 6 months in patients with low RAP 80 levels, 12 months in patients with intermediate RAP80 levels, and 11 months for those with high RAP 80 levels (Table 3).
###end p 34
###begin title 35
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Median survival for patients with low BRCA1 levels, treated with cisplatin plus gemcitabine, according to RAP 80 mRNA expression.
###end title 35
###begin p 36
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Median survival was not reached for 11 patients with low RAP 80 levels, 8 months for 9 patients with intermediate RAP 80 levels, and 7 months for 5 patients with high RAP 80 levels (P = 0.006).
###end p 36
###begin title 37
Median survival according to levels of BRCA1 and RAP80
###end title 37
###begin p 38
CI, confidence interval; NR, not reached
###end p 38
###begin p 39
###xml 219 226 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t004">Table 4</xref>
###xml 228 237 228 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s011">Figure S2</xref>
###xml 676 683 676 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t004">Table 4</xref>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 540 548 <span type="species:ncbi:9606">patients</span>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
In patients with low BRCA1 levels, time to progression was 14 months in patients with low RAP 80 levels, while it was 4 months for patients with intermediate RAP80 levels and 6 months for those with high RAP 80 levels (Table 4, Figure S2). In patients with intermediate BRCA1 levels, time to progression was 4 months in patients with low RAP 80 levels, while it was 9 months for patients with intermediate RAP 80 levels and 6 months for those with high RAP 80 levels. In patients with high BRCA1 levels, time to progression was 2 months in patients with low RAP 80 levels, 10 months in patients with intermediate RAP 80 levels, and 4 months for those with high RAP 80 levels (Table 4).
###end p 39
###begin title 40
Time to progression according to levels of BRCA1 and RAP 80
###end title 40
###begin p 41
CI, confidence interval
###end p 41
###begin p 42
All p-values were corrected using the Bonferroni method.
###end p 42
###begin p 43
###xml 134 143 134 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s005">Tables S4</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s006">S5</xref>
###xml 423 431 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s007">Table S6</xref>
###xml 695 703 695 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s008">Table S7</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
Similar results were obtained when median survival and time to progression were compared according to Abraxas mRNA expression levels (Tables S4 and S5). An exploratory multivariate analysis in the 86 patients, with the use of a Cox proportional-hazards model, identified ECOG performance status and RAP 80 as significant variables for survival (hazard ratios: performance status 1, 2.72; P = 0.005; RAP 80, 1.3; P = 0.05) (Table S6). Survival was not influenced by other clinical characteristics, types of metastases, second-line chemotherapy (36 patients), or Abraxas levels. The Cox model for time to progression also showed that only performance status and RAP 80 were significant variables (Table S7).
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Politi1">[26]</xref>
###xml 177 180 177 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Pao1">[7]</xref>
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Sequist1">[8]</xref>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Costa1">[10]</xref>
###xml 852 855 852 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Scagliotti1">[2]</xref>
###xml 1068 1071 1068 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Fossella1">[1]</xref>
###xml 1186 1189 1186 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Fossella1">[1]</xref>
###xml 1435 1442 1435 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t003">Table 3</xref>
###xml 1444 1452 1444 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005133-g003">Figure 3</xref>
###xml 2200 2204 2192 2196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang3">[27]</xref>
###xml 2309 2313 2301 2305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang2">[23]</xref>
###xml 2316 2320 2308 2312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Sobhian1">[24]</xref>
###xml 2328 2332 2320 2324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Kim1">[25]</xref>
###xml 2398 2402 2390 2394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang2">[23]</xref>
###xml 2873 2880 2865 2872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t003">Table 3</xref>
###xml 2955 2959 2947 2951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Lafarge1">[12]</xref>
###xml 2961 2965 2953 2957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn1">[17]</xref>
###xml 2967 2971 2959 2963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Quinn2">[19]</xref>
###xml 2973 2977 2965 2969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Wang1">[20]</xref>
###xml 3169 3176 3161 3168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t003">Table 3</xref>
###xml 3381 3388 3373 3380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t003">Table 3</xref>
###xml 3601 3605 3593 3597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Yan1">[28]</xref>
###xml 3757 3761 3749 3753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Schiller1">[29]</xref>
###xml 3785 3788 3777 3780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Scagliotti1">[2]</xref>
###xml 75 79 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 859 867 <span type="species:ncbi:9606">patients</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
###xml 1098 1105 <span type="species:ncbi:9606">patient</span>
###xml 1207 1215 <span type="species:ncbi:9606">patients</span>
###xml 1311 1319 <span type="species:ncbi:9606">patients</span>
###xml 2710 2718 <span type="species:ncbi:9606">patients</span>
###xml 2978 2986 <span type="species:ncbi:9606">patients</span>
###xml 3179 3187 <span type="species:ncbi:9606">Patients</span>
Mutations in the EGFR tyrosine kinase domain induce lung adenocarcinoma in mice[26] and a favorable response to first- and second-line gefitinib and erlotinib in advanced NSCLC.[7], [8] In the present study, median survival exceeded 28 months in 12 patients with EGFR mutations treated with erlotinib, with a median time to progression of 13 months and a two-year survival of 73.3%; these results are similar to the findings of a meta-analysis of prospective trials with gefitinib in patients with EGFR mutations.[10] Median survival was 11 months in patients with the lowest BRCA1 expression, treated with cisplatin plus gemcitabine, and two-year survival was 41.2%, which compares favorably with the median and two-year survival attained with gemcitabine plus cisplatin or pemetrexed plus cisplatin (10.3 months and 22%) in a recent randomized trial.[2] In patients with the highest BRCA1 expression, treated with docetaxel alone, median survival was 11 months, identical to that obtained in a large phase III trial in patients treated with docetaxel plus cisplatin.[1] However, in our study, no patient was alive at two years, while in the phase III trial, two-year survival was 21%.[1] Intriguingly, 11 patients with the lowest expression of both BRCA1 and RAP 80 had an outcome similar to that attained by patients with EGFR mutations treated with erlotinib: median survival was not reached and time to progression was 14 months (Table 3, Figure 3).Chemotherapy response is solidly based on the fact that DNA repair genes require a series of molecular recognition steps that enable DNA damage response proteins to localize at and near DNA lesions. Binding of the mediator of DNA damage checkpoint 1 (MDC1) protein to the phosphorylated tail of histone H2AX (gammaH2AX) facilitates the formation of BRCA1 nuclear foci at double-strand breaks induced by irradiation or chemotherapy. By dimerizing with BRCA1-associated RING domain (BARD1) protein through the RING domain, BRCA1 forms an E3 ubiquitin ligase. Recently, it has been shown that RAP 80 targets the BRCA1-BARD1 E3 ligase to MDC1-gammaH2AX-dependent lysine 63-linked ubiquitin proteins at double-strand breaks (reviewed in Wang & Elledge[27]). Three studies showed that the abrogation of RAP 80 reduced the formation of BRCA1-induced foci to 28%,[23] 2%[24] and 0%.[25] Moreover, Abraxas and RAP 80 foci formation is BRCA1-independent.[23] We therefore hypothesized that if RAP 80 was elevated, it could cause resistance to cisplatin-based chemotherapy even in the presence of low BRCA1 levels. The exploratory assessment of RAP 80 in the present study confirms its modulating effect on the BRCA1 customized model. For example, median survival in patients with the lowest BRCA1 expression decreased as RAP 80 expression increased: 8 months with intermediate RAP 80 levels and 7 months with high RAP 80 levels (Table 3). Overexpression of BRCA1 confers sensitivity to docetaxel and paclitaxel;[12], [17], [19], [20] patients with the highest levels of BRCA1, treated with docetaxel, had a median survival of 11-12 months when RAP80 expression was also high but only 6 months when RAP 80 expression was low (Table 3). Patients with intermediate BRCA1 levels, treated with cisplatin plus docetaxel, had an overall median survival of 9 months, which increased to 13-16 months when RAP 80 levels were intermediate or high (Table 3). These results can be explained by pre-clinical findings that RAP 80 is able to translocate to irradiation-induced foci in HCC1937 cells which express a truncated BRCA1 that is unable to migrate to nuclear foci.[28] This indicates that RAP 80 could replace the BRCA1 DNA repair function in cells lacking BRCA1. Thus, although different platinum doublets show the same[29] - or slightly different[2] - survival overall, differences could be found when customizing chemotherapy based on a model of BRCA1 and RAP 80.
###end p 45
###begin p 46
###xml 391 399 391 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s005">Table S4</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
In the present study, no correlation was found between BRCA1 and Abraxas mRNA expression. However, there was an indication that expression levels of Abraxas modulate the effect of BRCA1. For example, patients with the lowest BRCA1 expression, treated with cisplatin plus gemcitabine, attained a median survival of 18 months and time to progression of 11 months when Abraxas levels were low (Table S4).
###end p 46
###begin p 47
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Deeb1">[30]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Rosell1">[31]</xref>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
In addition to the potential predictive role of BRCA1, BRCA1 overexpression confers aggressive behavior in transgenic models of small cell and squamous cell lung carcinomas, as well as in a subset of lung adenocarcinomas harboring the intrinsic T/t-antigen cancer signature.[30] Poor prognosis has also been associated with BRCA1 overexpression in early NSCLC.[31] In the present study, two-year survival was 41% in patients with the lowest levels of BRCA1, 16% in those with intermediate levels and 0% in those with the highest levels.
###end p 47
###begin p 48
###xml 302 306 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Ayoub1">[32]</xref>
###xml 422 426 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-P1">[33]</xref>
###xml 521 525 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Marsit1">[34]</xref>
###xml 721 725 709 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-GarciaCao1">[35]</xref>
The mechanisms of BRCA1 overexpression or downregulation in NSCLC remain to be clarified. However, it has recently been shown that DNA breaks swiftly activate heterochromatin protein 1-beta (HP1-beta), which promotes histone H2AX phosphorylation, initiating the BRCA1 signaling assembly for DNA repair.[32] Intriguingly, casein kinase 2 promotes the mobilization of HP1-beta and is associated with poor prognosis in NSCLC.[33] While BRCA1 methylation is observed in ductal breast cancer, it is only found in 4% of NSCLCs.[34] Low BRCA1 expression in tumors may be due to the loss of histone methyltransferases, which leads to decreased chromatin H3 methylation in lysine 9, with the consequent downregulation of HP1-beta.[35]
###end p 48
###begin p 49
###xml 700 704 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005133-Boukovinas1">[36]</xref>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 958 966 <span type="species:ncbi:9606">Patients</span>
In this phase II, non-randomized study, the genetic factor and treatment difference are entirely co-existing, and caution should be exercised when interpreting the results. However, the exploratory analysis indicates that there is some evidence for tailoring chemotherapy based on BRCA1 and RAP 80 levels. Moreover, in a recent study of 96 stage IV NSCLC patients treated with docetaxel plus gemcitabine, we observed that as BRCA1 mRNA levels increased, the probability of response increased and the risk of progression decreased. For patients with the highest BRCA1 levels, the response rate was 58.6%, compared to 13.8% for those with intermediate levels and 27.6% for those with the lowest levels.[36] Based on these findings and those of the present study, the Spanish Lung Cancer Group is now modifying the protocol for a planned international phase III trial in advanced NSCLC to include customization based on RAP 80 as well as BRCA1 mRNA expression. Patients in the control arm will receive cisplatin plus docetaxel and those in the experimental arm will receive chemotherapy based on RAP 80 and BRCA1 mRNA levels: low RAP 80 levels (regardless of BRCA1 levels), cisplatin plus gemcitabine; intermediate or high RAP 80 and low or intermediate BRCA1, cisplatin plus docetaxel; intermediate or high RAP 80 and high BRCA1, docetaxel alone.
###end p 49
###begin title 50
Materials and Methods
###end title 50
###begin p 51
###xml 72 83 72 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s012">Protocol S1</xref>
###xml 88 99 88 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s013">Protocol S2</xref>
The protocol for this trial is available as supporting information; see Protocol S1 and Protocol S2.
###end p 51
###begin title 52
Ethics statement
###end title 52
###begin p 53
###xml 86 94 <span type="species:ncbi:9606">patients</span>
The protocol was approved by each center's institutional ethics review board, and all patients provided written informed consent before enrollment.
###end p 53
###begin title 54
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 54
###begin p 55
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">Patients</span>
We recruited patients to this phase II prospective multicenter trial based on screening of EGFR mutations followed by BRCA1 mRNA expression analysis in paraffin-embedded tumor tissue. Clinical eligibility included stage IIIB with pleural effusion or stage IV NSCLC, measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), performance status 0-2 by Eastern Cooperative Oncology Group (ECOG) criteria, adequate hematologic, renal and hepatic function. Brain metastases were allowed. Patients with squamous cell tumors, prior systemic therapy for advanced NSCLC, or other clinically significant cancers within five years were not eligible.
###end p 55
###begin p 56
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 599 600 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 210 218 <span type="species:ncbi:9606">Patients</span>
###xml 300 308 <span type="species:ncbi:9606">Patients</span>
###xml 433 441 <span type="species:ncbi:9606">Patients</span>
###xml 541 549 <span type="species:ncbi:9606">Patients</span>
Patients with EGFR mutations - either the exon 19 deletion or the L858R mutation - received 150 mg of daily oral erlotinib continuously until progression or intolerable adverse effects. Each cycle was 28 days. Patients with wild-type EGFR received customized chemotherapy based on BRCA1 mRNA levels. Patients in the lowest tercile of BRCA1 expression received cisplatin 75 mg/m2 on day 1 plus gemcitabine 1250 mg/m2 on days 1 and 8. Patients in the intermediate tercile received cisplatin 75 mg/m2 on day 1 plus docetaxel 75 mg/m2 on day 1. Patients in the highest tercile received docetaxel 75 mg/m2 on day 1. All chemotherapy was repeated every three weeks for a maximum of six cycles unless there was earlier evidence of disease progression or intolerable adverse effects.
###end p 56
###begin p 57
Baseline assessment included a medical history, physical examination and tumor measurements of palpable lesions as well as lesions assessed by computed tomography scans. The baseline assessment method was repeated every other cycle, and then every six weeks until disease progression.
###end p 57
###begin title 58
Molecular analyses
###end title 58
###begin title 59
Tumor tissue collection and laser capture microdissection
###end title 59
###begin p 60
BRCA1, RAP80 and Abraxas gene expression and EGFR mutations were analyzed in RNA and DNA isolated from paraffin-embedded tumor tissues. For each tumor sample a haematoxylin/eosin stained slice was analyzed by our pathologist to select the tumor area. Two 5-micron slices were mounted on special slides (Pem-Membrane slides, Palm, Oberlensheim, Germany) for laser capture microdissection (CAPmover Microdissector, Carl Zeiss Microimaging, Barcelona, Spain) to ensure a minimum of 90% of tumor cells. One slide was used for RNA isolation and the second was used for DNA isolation.
###end p 60
###begin title 61
Gene expression analysis
###end title 61
###begin p 62
###xml 297 305 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s009">Table S8</xref>
Gene expression analysis was performed in RNA isolated from the tumor tissue specimens. cDNA was synthesized using M-MLV retrotranscriptase enzyme. Template cDNA was added to Taqman Universal Master Mix (AB; Applied Biosystems, Foster City, CA, USA) with specific primers and probe for each gene (Table S8). The primer and probe sets were designed using Primer Express 2.0 Software (AB) and the RefSeq sequences (). Quantification of gene expression was performed using the ABI Prism 7900HT Sequence Detection System (AB).
###end p 62
###begin title 63
EGFR mutation analysis
###end title 63
###begin p 64
For isolation of DNA from microdissected tissue, the material was incubated with proteinase K and DNA was extracted with phenol-chloroform and ethanol precipitation. Primers for PCR amplification in nested reactions for exons 19 and 21 of EGFR are shown in the supporting information. Mutations were analyzed using two methods: DNA sequencing and length analysis of fluorescently labeled PCR products for EGFR deletions in exon 19, and sequencing and 5' nuclease activity assay (TaqMan) for EGFR mutation in exon 21 (L858R).
###end p 64
###begin p 65
###xml 52 59 52 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005133.s001">Text S1</xref>
(For further details on the molecular analyses, see Text S1).
###end p 65
###begin title 66
Statistical analysis
###end title 66
###begin p 67
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
Patients were divided into groups based on terciles of BRCA1 expression since this division is less susceptible to bias in multiple comparisons. Cut-off points for the BRCA1 terciles were obtained from the Spanish Lung Cancer Group data base, which includes clinical and genetic characteristics of more than 600 Spanish lung cancer patients. Responses were recorded according to the RECIST criteria. Median time to progression and overall survival were calculated from the start of treatment to the first documented disease progression or death, respectively.
###end p 67
###begin p 68
###xml 49 57 <span type="species:ncbi:9606">patients</span>
In order to compare quantitative variables among patients in each of the treatment groups, to explore associations between variables within each group, and to study the potential association between baseline characteristics and response, we used parametric tests (student's t-test or ANOVA) or their equivalent non-parametric tests (U Mann-Whitney, Kruskall Wallis) when normality did not hold. The normality of continuous variables was checked with the Kolmogorov-Smirnov test. In order to compare categorical variables and response percentages with their 95% CIs among treatment groups, we used either the two-sided Fisher's exact test or the Chi-square test.
###end p 68
###begin p 69
The association of risk factors with time-to-event endpoints was analyzed with the two-sided logrank test, and the Kaplan-Meier method was used to plot the corresponding time-to-progression and survival curves. A univariate Cox regression analysis, with hazard ratios and their 95% CIs was used to assess the association between each potential prognostic factor and survival and time to progression. These factors were then included in a multivariate Cox proportional hazards regression model to evaluate the independent significance of each variable on survival and time to progression. The likelihood ratio test was used to assess the goodness of fit, and the Wald's test was used to assess the coefficient significance. For potential multiple comparisons, the p-values were corrected with the Bonferroni correction.
###end p 69
###begin p 70
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Eighty-six of the 111 patients without EGFR mutations for whom sufficient tumor tissue was available were included in an exploratory sub-analysis of the relation between BRCA1, RAP80 and Abraxas expression. Spearman's rank test was used to evaluate the correlation between BRCA1, RAP80 and ABRAXAS mRNA expression.
###end p 70
###begin p 71
All statistical calculations were performed with the SPSS software statistical package, version 15.0 (SPSS, Inc., Chicago, IL, USA) and S-PLUS 6.1. Two-sided p-values of less than 0.05 were considered significant.
###end p 71
###begin title 72
Supporting Information
###end title 72
###begin p 73
Supplemental text
###end p 73
###begin p 74
(0.04 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Clinicopathological characteristics, gene expression levels, EGFR mutation status, and outcomes for all patients
###end p 76
###begin p 77
(0.07 MB XLS)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
Types of metastases
###end p 79
###begin p 80
(0.05 MB DOC)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Characteristics of 86 patients in whom RAP 80 and Abraxas were analyzed
###end p 82
###begin p 83
(0.07 MB DOC)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
Median survival according to levels of BRCA1 and Abraxas
###end p 85
###begin p 86
(0.03 MB DOC)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
Time to progression according to levels of BRCA1 and Abraxas
###end p 88
###begin p 89
(0.03 MB DOC)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin p 91
Multivariable COX model for survival with BRCA1 and RAP 80 as continuous variables
###end p 91
###begin p 92
(0.03 MB DOC)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin p 94
Multivariable COX model for time to progression with BRCA1 and RAP 80 as continuous variables
###end p 94
###begin p 95
(0.03 MB DOC)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin p 97
Primers and probes used in gene expression analyses
###end p 97
###begin p 98
(0.04 MB DOC)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin p 100
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t002">Table 2</xref>
Time to progression according to treatment group. Time to progression was 13 months in the EGFR group, 5 months in the low and intermediate BRCA1 groups, and 8 months in the high BRCA1 group (see Table 2).
###end p 100
###begin p 101
(8.92 MB TIF)
###end p 101
###begin p 102
Click here for additional data file.
###end p 102
###begin p 103
###xml 270 277 270 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005133-t004">Table 4</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Time to progression for patients in the low BRCA1 group according to RAP 80 expression levels. Time to progression was 14 months for patients with low RAP 80 levels, 4 months for those with intermediate RAP 80 levels, and 6 months for those with high RAP 80 levels (see Table 4).
###end p 103
###begin p 104
(10.31 MB TIF)
###end p 104
###begin p 105
Click here for additional data file.
###end p 105
###begin p 106
Trial Protocol
###end p 106
###begin p 107
(1.12 MB PDF)
###end p 107
###begin p 108
Click here for additional data file.
###end p 108
###begin p 109
English summary of protocol
###end p 109
###begin p 110
(0.21 MB PDF)
###end p 110
###begin p 111
Click here for additional data file.
###end p 111
###begin title 112
References
###end title 112
###begin article-title 113
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
###end article-title 113
###begin article-title 114
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
###end article-title 114
###begin article-title 115
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
###end article-title 115
###begin article-title 116
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.
###end article-title 116
###begin article-title 117
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
###end article-title 117
###begin article-title 118
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
###end article-title 118
###begin article-title 119
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
###end article-title 119
###begin article-title 120
###xml 24 32 <span type="species:ncbi:9606">patients</span>
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
###end article-title 120
###begin article-title 121
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
###end article-title 121
###begin article-title 122
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
###end article-title 122
###begin article-title 123
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
###end article-title 123
###begin article-title 124
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
###end article-title 124
###begin article-title 125
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
###end article-title 125
###begin article-title 126
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
###end article-title 126
###begin article-title 127
BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.
###end article-title 127
###begin article-title 128
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
###end article-title 128
###begin article-title 129
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
###end article-title 129
###begin article-title 130
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
###end article-title 130
###begin article-title 131
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy.
###end article-title 131
###begin article-title 132
ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
###end article-title 132
###begin article-title 133
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
###end article-title 133
###begin article-title 134
The DNA damage response: ten years after.
###end article-title 134
###begin article-title 135
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.
###end article-title 135
###begin article-title 136
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.
###end article-title 136
###begin article-title 137
Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response.
###end article-title 137
###begin article-title 138
###xml 32 36 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
###end article-title 138
###begin article-title 139
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage.
###end article-title 139
###begin article-title 140
The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response.
###end article-title 140
###begin article-title 141
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
###end article-title 141
###begin article-title 142
###xml 32 36 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
###end article-title 142
###begin article-title 143
BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer.
###end article-title 143
###begin article-title 144
HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response.
###end article-title 144
###begin article-title 145
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.
###end article-title 145
###begin article-title 146
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival.
###end article-title 146
###begin article-title 147
Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases.
###end article-title 147
###begin article-title 148
###xml 143 151 <span type="species:ncbi:9606">patients</span>
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
###end article-title 148
###begin p 149
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 149
###begin p 150
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study received partial support from Redes de Cancer, Spain (grant RD06/0020/0056). The funding source was not involved in the collection, analysis or interpretation of the data, the writing of the report, or the decision to submit for publication.
###end p 150

